- Home
- TAK vs HLN Comparison
TAK vs HLN Comparison
Compare TAK & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAK
- HLN
- Stock Information
- Founded
- TAK 1781
- HLN 2022
- Country
- TAK Japan
- HLN United Kingdom
- Employees
- TAK N/A
- HLN N/A
- Industry
- TAK Biotechnology: Pharmaceutical Preparations
- HLN Package Goods/Cosmetics
- Sector
- TAK Health Care
- HLN Consumer Discretionary
- Exchange
- TAK Nasdaq
- HLN Nasdaq
- Market Cap
- TAK 47.5B
- HLN 48.2B
- IPO Year
- TAK N/A
- HLN N/A
- Fundamental
- Price
- TAK $14.49
- HLN $9.49
- Analyst Decision
- TAK
- HLN Buy
- Analyst Count
- TAK 0
- HLN 1
- Target Price
- TAK N/A
- HLN $10.95
- AVG Volume (30 Days)
- TAK 5.7M
- HLN 12.0M
- Earning Date
- TAK 07-30-2025
- HLN 08-19-2025
- Dividend Yield
- TAK 3.76%
- HLN 1.86%
- EPS Growth
- TAK N/A
- HLN 41.64
- EPS
- TAK 0.59
- HLN 0.23
- Revenue
- TAK $31,053,301,865.00
- HLN $15,096,588,575.00
- Revenue This Year
- TAK $0.47
- HLN $1.93
- Revenue Next Year
- TAK $0.80
- HLN $4.10
- P/E Ratio
- TAK $47.52
- HLN $20.57
- Revenue Growth
- TAK 1.52
- HLN N/A
- 52 Week Low
- TAK $12.80
- HLN $8.86
- 52 Week High
- TAK $15.53
- HLN $11.42
- Technical
- Relative Strength Index (RSI)
- TAK 49.01
- HLN 42.06
- Support Level
- TAK $13.49
- HLN $9.23
- Resistance Level
- TAK $14.29
- HLN $9.76
- Average True Range (ATR)
- TAK 0.22
- HLN 0.12
- MACD
- TAK 0.03
- HLN 0.01
- Stochastic Oscillator
- TAK 69.71
- HLN 39.86
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About HLN Haleon plc (Each representing two)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.